Bolt Biotherapeutics has the GF Score of 55, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Bolt Biotherapeutics
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Bolt Biotherapeutics GF Score Related Terms
BOLT vs AIM, ERNA, RVPH: GF Score Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's GF Score falls into.
Bolt Biotherapeutics (BOLT) has a GF Score of 55 as of Jun. 29, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bolt Biotherapeutics and its competitors. This is 175% above median its historical median of 20.00. Over the past decade, Bolt Biotherapeutics' GF Score has ranged from 10.00 to 63.00.
Is Bolt Biotherapeutics' GF Score too high?
Bolt Biotherapeutics' current GF Score of 55 is 175% above median its 10-year median of 20.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 63.00. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' GF Score compare to AIM and ERNA?
Bolt Biotherapeutics' GF Score of 55 can be compared against companies in the Biotechnology industry. Historically, Bolt Biotherapeutics' own GF Score has ranged from 10.00 to 63.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current GF Score is 55, which is 175% above median its own 10-year median of 20.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.03, compared to a current price of $4.05 — trading 55.1% below its estimated fair value. The current GF Score is 55, which is 175% above median its 10-year median of 20.00. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current GF Score is 55 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of $4.05 is trading 55.1% below its estimated GF Value™ of $9.03.
GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.
Key valuation signals for BOLT:
GF Score: 55 (175% above median its 10-year median of 20.00)
GF Value™: $9.03 vs. price of $4.05 (55.1% below fair value)
No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score
Get the complete analysis for BOLT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLT has been successfully added to your 